Insights into the mode of action of 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89) against adult Schistosoma mansoni worms

Emmanuel Awusah Blay, Takashi Kumagai, Masafumi Yamabe, Akina Hino, Rieko Shimogawara, Hye-Sook Kim, Akira Sato, Koichiro Ichimura, Irene Ayi, Shiroh Iwanaga, Nobuo Ohta

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Control of morbidity associated with schistosomiasis via chemotherapy largely relies on the drug praziquantel. Repeated therapy with praziquantel has created concerns about the possible selection of resistant worms and necessitated the search for novel drugs to treat schistosomiasis. Here, a murine model was infected with Schistosoma mansoni and treated with oral 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89), which caused a significant reduction in fecundity and egg burden and reduced morbidity when administered at 5-weeks post-infection. The analysis showed that the mode of action occurred through the ingestion of activated N-89 by the worms, and that there was no direct external effect on the S. mansoni worms. Ultrastructural analysis of the treated worms showed disruptions in the gut lumen and the presence of large volumes of material, suggestive of undigested blood meals or red blood cells. In addition, there were reduced vitelline cells in female worms and damage to sub-tegmental musculature in male worms. Eggs recovered from the treated mice showed both damage to the eggs and the production of immature eggs. Expression of mRNA responsible for gut and digestive function and egg production was also significantly affected by N-89 treatment, whereas control genes for musculature showed no significant changes. Thus, N-89 drastically affected the total digestive function and egg production of S. mansoni worms. Physiological processes requiring heme uptake such as egg production and eggshell formation were subsequently affected, suggesting that the compound could be a possible therapeutic drug candidate for schistosomiasis control.

Original languageEnglish
Pages (from-to)403-412
Number of pages10
JournalParasitology International
Volume67
Issue number4
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Schistosoma mansoni
Ovum
Schistosomiasis
Eggs
Praziquantel
Pharmaceutical Preparations
Egg Shell
Physiological Phenomena
Morbidity
Heme
Fertility
Meals
Therapeutics
Eating
Erythrocytes
Drug Therapy
Messenger RNA
1,2,6,7-tetraoxaspiro(7.11)nonadecane
Infection
Genes

Keywords

  • 1,2,6,7-Tetraoxaspiro [7.11] nonadecane
  • Novel treatment
  • Schistosoma mansoni
  • Schistosomiasis

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

Insights into the mode of action of 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89) against adult Schistosoma mansoni worms. / Blay, Emmanuel Awusah; Kumagai, Takashi; Yamabe, Masafumi; Hino, Akina; Shimogawara, Rieko; Kim, Hye-Sook; Sato, Akira; Ichimura, Koichiro; Ayi, Irene; Iwanaga, Shiroh; Ohta, Nobuo.

In: Parasitology International, Vol. 67, No. 4, 01.08.2018, p. 403-412.

Research output: Contribution to journalArticle

Blay, EA, Kumagai, T, Yamabe, M, Hino, A, Shimogawara, R, Kim, H-S, Sato, A, Ichimura, K, Ayi, I, Iwanaga, S & Ohta, N 2018, 'Insights into the mode of action of 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89) against adult Schistosoma mansoni worms', Parasitology International, vol. 67, no. 4, pp. 403-412. https://doi.org/10.1016/j.parint.2018.03.006
Blay, Emmanuel Awusah ; Kumagai, Takashi ; Yamabe, Masafumi ; Hino, Akina ; Shimogawara, Rieko ; Kim, Hye-Sook ; Sato, Akira ; Ichimura, Koichiro ; Ayi, Irene ; Iwanaga, Shiroh ; Ohta, Nobuo. / Insights into the mode of action of 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89) against adult Schistosoma mansoni worms. In: Parasitology International. 2018 ; Vol. 67, No. 4. pp. 403-412.
@article{8f28e3df5042405583e0c3f16ee4ac01,
title = "Insights into the mode of action of 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89) against adult Schistosoma mansoni worms",
abstract = "Control of morbidity associated with schistosomiasis via chemotherapy largely relies on the drug praziquantel. Repeated therapy with praziquantel has created concerns about the possible selection of resistant worms and necessitated the search for novel drugs to treat schistosomiasis. Here, a murine model was infected with Schistosoma mansoni and treated with oral 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89), which caused a significant reduction in fecundity and egg burden and reduced morbidity when administered at 5-weeks post-infection. The analysis showed that the mode of action occurred through the ingestion of activated N-89 by the worms, and that there was no direct external effect on the S. mansoni worms. Ultrastructural analysis of the treated worms showed disruptions in the gut lumen and the presence of large volumes of material, suggestive of undigested blood meals or red blood cells. In addition, there were reduced vitelline cells in female worms and damage to sub-tegmental musculature in male worms. Eggs recovered from the treated mice showed both damage to the eggs and the production of immature eggs. Expression of mRNA responsible for gut and digestive function and egg production was also significantly affected by N-89 treatment, whereas control genes for musculature showed no significant changes. Thus, N-89 drastically affected the total digestive function and egg production of S. mansoni worms. Physiological processes requiring heme uptake such as egg production and eggshell formation were subsequently affected, suggesting that the compound could be a possible therapeutic drug candidate for schistosomiasis control.",
keywords = "1,2,6,7-Tetraoxaspiro [7.11] nonadecane, Novel treatment, Schistosoma mansoni, Schistosomiasis",
author = "Blay, {Emmanuel Awusah} and Takashi Kumagai and Masafumi Yamabe and Akina Hino and Rieko Shimogawara and Hye-Sook Kim and Akira Sato and Koichiro Ichimura and Irene Ayi and Shiroh Iwanaga and Nobuo Ohta",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.parint.2018.03.006",
language = "English",
volume = "67",
pages = "403--412",
journal = "Parasitology International",
issn = "1383-5769",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - Insights into the mode of action of 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89) against adult Schistosoma mansoni worms

AU - Blay, Emmanuel Awusah

AU - Kumagai, Takashi

AU - Yamabe, Masafumi

AU - Hino, Akina

AU - Shimogawara, Rieko

AU - Kim, Hye-Sook

AU - Sato, Akira

AU - Ichimura, Koichiro

AU - Ayi, Irene

AU - Iwanaga, Shiroh

AU - Ohta, Nobuo

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Control of morbidity associated with schistosomiasis via chemotherapy largely relies on the drug praziquantel. Repeated therapy with praziquantel has created concerns about the possible selection of resistant worms and necessitated the search for novel drugs to treat schistosomiasis. Here, a murine model was infected with Schistosoma mansoni and treated with oral 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89), which caused a significant reduction in fecundity and egg burden and reduced morbidity when administered at 5-weeks post-infection. The analysis showed that the mode of action occurred through the ingestion of activated N-89 by the worms, and that there was no direct external effect on the S. mansoni worms. Ultrastructural analysis of the treated worms showed disruptions in the gut lumen and the presence of large volumes of material, suggestive of undigested blood meals or red blood cells. In addition, there were reduced vitelline cells in female worms and damage to sub-tegmental musculature in male worms. Eggs recovered from the treated mice showed both damage to the eggs and the production of immature eggs. Expression of mRNA responsible for gut and digestive function and egg production was also significantly affected by N-89 treatment, whereas control genes for musculature showed no significant changes. Thus, N-89 drastically affected the total digestive function and egg production of S. mansoni worms. Physiological processes requiring heme uptake such as egg production and eggshell formation were subsequently affected, suggesting that the compound could be a possible therapeutic drug candidate for schistosomiasis control.

AB - Control of morbidity associated with schistosomiasis via chemotherapy largely relies on the drug praziquantel. Repeated therapy with praziquantel has created concerns about the possible selection of resistant worms and necessitated the search for novel drugs to treat schistosomiasis. Here, a murine model was infected with Schistosoma mansoni and treated with oral 1,2,6,7-tetraoxaspiro [7.11] nonadecane (N-89), which caused a significant reduction in fecundity and egg burden and reduced morbidity when administered at 5-weeks post-infection. The analysis showed that the mode of action occurred through the ingestion of activated N-89 by the worms, and that there was no direct external effect on the S. mansoni worms. Ultrastructural analysis of the treated worms showed disruptions in the gut lumen and the presence of large volumes of material, suggestive of undigested blood meals or red blood cells. In addition, there were reduced vitelline cells in female worms and damage to sub-tegmental musculature in male worms. Eggs recovered from the treated mice showed both damage to the eggs and the production of immature eggs. Expression of mRNA responsible for gut and digestive function and egg production was also significantly affected by N-89 treatment, whereas control genes for musculature showed no significant changes. Thus, N-89 drastically affected the total digestive function and egg production of S. mansoni worms. Physiological processes requiring heme uptake such as egg production and eggshell formation were subsequently affected, suggesting that the compound could be a possible therapeutic drug candidate for schistosomiasis control.

KW - 1,2,6,7-Tetraoxaspiro [7.11] nonadecane

KW - Novel treatment

KW - Schistosoma mansoni

KW - Schistosomiasis

UR - http://www.scopus.com/inward/record.url?scp=85056248011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056248011&partnerID=8YFLogxK

U2 - 10.1016/j.parint.2018.03.006

DO - 10.1016/j.parint.2018.03.006

M3 - Article

VL - 67

SP - 403

EP - 412

JO - Parasitology International

JF - Parasitology International

SN - 1383-5769

IS - 4

ER -